Brave Asset Management’s CRISPR Therapeutics CRSP Stock Holding History

Brave Asset Management’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$613K	Sell	11,234 -6,800	-38%	-$358K	0.13%	71
2026 Q1	$858K	Hold	18,034	–	–	0.2%	53
2025 Q4	$946K	Buy	18,034 +5,000	+38%	+$299K	0.22%	45
2025 Q3	$845K	Sell	13,034 -500	-4%	-$28.7K	0.2%	54
2025 Q2	$658K	Buy	13,534 +8,125	+150%	+$314K	0.18%	68
2025 Q1	$184K	Sell	5,409 -2,150	-28%	-$91.1K	0.06%	137
2024 Q4	$298K	Hold	7,559	–	–	0.09%	103
2024 Q3	$355K	Hold	7,559	–	–	0.09%	95
2024 Q2	$408K	Sell	7,559 -889	-11%	-$51.4K	0.1%	82
2024 Q1	$576K	Buy	8,448 +1,393	+20%	+$99.7K	0.15%	67
2023 Q4	$442K	Buy	7,055 +2,389	+51%	+$132K	0.12%	76
2023 Q3	$212K	Buy	4,666 +1	+0%	+$52	0.06%	113
2023 Q2	$262K	Sell	4,665 -983	-17%	-$55.8K	0.08%	101
2023 Q1	$255K	Buy	+5,648	New	+$274K	0.08%	103
2022 Q2	–	Sell	-3,500	Closed	-$220K	–	153
2022 Q1	$220K	Hold	3,500	–	–	0.08%	130
2021 Q4	$265K	Buy	3,500 +1,000	+40%	+$87.4K	0.07%	115
2021 Q3	$280K	Buy	+2,500	New	+$314K	0.08%	108

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GSK plc London $602M AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Brave Asset Management's CRSP Position: Q2 2026 in Review

Brave Asset Management reduced its CRISPR Therapeutics (CRSP) stake by 38% in Q2 2026, selling an estimated $358K and leaving 11,234 shares worth $613K. The position accounts for 0.13% of the portfolio, ranked #71.

Brave Asset Management first reported a position in CRSP in Q3 2021 and has held it in 17 quarters since. The position peaked at $946K in Q4 2025. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

Brave Asset Management held 11,234 shares of CRISPR Therapeutics worth $613K as of Q2 2026.
Brave Asset Management sold 6,800 CRISPR Therapeutics shares in Q2 2026, an estimated $358K.
CRISPR Therapeutics made up 0.13% of Brave Asset Management's portfolio in Q2 2026, its #71 holding.
Brave Asset Management first reported a position in CRISPR Therapeutics in Q3 2021 and has held it in 17 quarters since.
Brave Asset Management's CRISPR Therapeutics position peaked at $946K in Q4 2025.
521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Brave Asset Management's 13F filing for Q2 2026, filed 8 Jul 2026.